Effect of a thrombolytic agent (urokinase) on necrosis after acute myocardial infarction

Citation for published version (APA):

Document status and date:
Published: 01/01/1975

Document Version:
Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 05 May. 2020
EFFECT OF A THROMBOLYTIC AGENT (UROKINASE) ON NECROSIS AFTER ACUTE MYOCARDIAL INFARCTION

W. T. HERMENS,2 S. A. G. J. WITTEVEEN, L. HOLLAAR, and H. C. HEMKER2

SUMMARY

Using a two-compartment model with continuous input function, the rate and extent of myocardial damage were calculated from plasma enzyme levels measured in patients suffering from acute myocardial infarction (AMI). Results were compared for four different enzymes. As regards the course of necrosis, two different hypotheses were tested and it was shown that the necrotic process has to be considered as a multiplicative process rather than as a sudden disintegration of cells due to anoxia. Comparison of results obtained in a group of 5 patients treated with urokinase and in an untreated control group of 10 patients showed that the necrotic phase as defined by the enzyme release from the infarcted area was significantly shortened.

INTRODUCTION

The importance of determining plasma enzyme levels in patients suffering from acute myocardial infarction (AMI) has been well established. However, these data are mainly used in a qualitative way for diagnostic or prognostic reasons. As the routine laboratory determinations of these enzymes are sufficiently accurate to allow a thorough analysis of enzyme levels as a function of time, much information is lost that way. In the last few years, we have developed a method of obtaining a quantitative analysis of myocardial damage after AMI (Hemker et al., 1972; Witteveen, 1972). In the present paper, this method is used to investigate the effect of urokinase on the necrotic process after AMI.

MATERIALS AND METHODS

The experimental group consisted of 15 patients with AMI, of whom 5 received urokinase. Patients with cardiogenic shock or severe heart failure were not...
included in the investigation. For further clinical details see the publication by Witteveen (1972).

Blood was drawn from an indwelling catheter as soon as possible after admission to hospital and, subsequently, every 4 hours for 2 or 3 days. At the end of this period, progressively fewer samples were taken until plasma levels returned to normal.

Samples consisted of 10 ml of blood collected in tubes containing 0.2 ml of 20% sodium citrate to prevent clotting and were immediately centrifuged, initially for 10 min at 900 g to remove erythrocytes and leukocytes, and subsequently for 20 min at 40,000 g to remove thrombocytes. The plasma was then stored at -20°C until enzyme determinations were carried out.

The following enzymes were studied: glutamic oxalacetic transaminase (GOT; E.C. 2.6.1.1), creatine phosphokinase (CPK; E.C. 2.7.3.2), phosphohexose isomerase (PHI; E.C. 5.3.1.9), lactate dehydrogenase (LDH, E.C. 1.1.1.27), and α-hydroxybutyrate dehydrogenase (α-HBDH; E.C. 1.1.1.27). The last two enzymes are identical but are determined in a different assay, so that comparison of results permits an estimation of over-all experimental error.

Enzyme determinations were done spectrophotometrically. For GOT, LDH, and α-HBDH commercially available test kits were used (Boehringer). Recently, Boehringer introduced so-called optimized test kits. If these are used, the results presented below should be adjusted. CPK was determined according to Rosalki, (1967), and PHI according to Weber and Wegmann (1968). Enzyme activities were expressed as I.U./liter, in which 1 I.U. catalyzes the turnover of 1 μmole of substrate per minute.

Urokinase, a nonantigenic thrombolytic agent acting through activation of plasminogen, was made available by Hoffmann La Roche. The drug was administered as soon as possible after admission to hospital. An initial loading dose of 7,200 units/kg body weight was given in 10 min, after which an infusion of 3,600 units/hour/kg body weight was given for 18 hours.

Heart tissue was obtained at thoracic surgery. To determine the enzyme activities in the normal myocardium, the tissue was kept in physiological saline at 0°C and homogenized within 10–15 min (Turrax). After sedimentation of the remaining particles, the activities were measured in the supernatant (Table 2). To study the shed-out of enzymes in vitro, tissue was kept at 37°C for up to 100 hours in plasma under anoxic conditions and gentle shaking; the activity appearing in the plasma was measured. After this period, the tissue was homogenized to obtain the residual tissue activity (Table 1). The molecular weights of the human enzymes were determined by column chromatography with DEAE Sephadex G-200 of plasma containing high activities. To obtain a standard, albumin (M = 69,000) and ceruloplasmin (M = 160,000) were also determined by quantitative immunoelectrophoresis (Laurell).

The mathematical analysis of the patient data is based upon the two-compartment-
Urokinase after Acute Myocardial Infarction

ment model presented in Figure 1, where \( V_1 \) is the vascular volume, \( V_2 \) the extravascular volume, \( F(t) \) the enzyme release as a function of time, \( k \) the sum of first order clearance constants, and \( D \) the diffusion constant. This model is based upon the following considerations. The observed (double) exponential clearance from the plasma indicates that there is only first order elimination proportional to the enzyme concentration.

The assumption of the absence of extravascular elimination is based upon the in vitro experiments showing no appreciable denaturation. This suggests that the enzyme breakdown is circulation-dependent. Insofar as the enzymes from the necrotic cells do not diffuse directly into the blood stream, we assumed that, in view of the relatively direct transport of lymph from the myocardium to the vascular compartment by way of the thoracic duct, the input \( F(t) \) is only into \( V_1 \). A more detailed discussion of the implicit assumptions of this model will be published elsewhere (Hermens et al.). It can be shown (Witteveen, 1972) that the plasma concentration of enzyme as a function of time \( X(t) \) in this model is given by the double exponential function

\[
X(t) = C_1(t)e^{-a_1t} + C_2(t)e^{-a_2t} + X_n
\]

\((a_1 > a_2 > 0)\), where \( X_n \) is the normal steady state enzyme concentration, and the constants \( a_1 \) and \( a_2 \) depend on \( V_1 \), \( V_2 \), \( k \), and \( D \). The time-dependent coefficients in Eq. (1) are given by:

\[
C_1(t) = \left[ (a_1 - a_1a_2/k)/(a_1 - a_2) \right] \int_0^t f(t)e^{a_1\tau}d\tau
\]

\[
C_2(t) = \left[ (a_1a_2/k-a_2)/(a_1-a_2) \right] \int_0^t f(t)e^{a_2\tau}d\tau
\]

where \( f(t) = F(t)/V_1kX_n = \) extra enzyme release (i.e., due to infarction) per liter vascular volume.

As soon as the enzyme release from the infarcted area is completed, i.e., \( f(t) = 0 \), \( C_1(t) \) and \( C_2(t) \) become constants and a logarithmic plot gives a curve with slopes \( a_1 \) and \( a_2 \) as shown in Figure 1.

The vascular volume \( V_1 \) was calculated from body weight and hematocrit. The remaining parameters, \( k \), \( V_2 \), and permeability constant \( P \) (which is related to the diffusion constant \( D \) by \( P = DS/6 \), where \( S \) and \( b \) are the total interface area and the characteristic thickness of the membrane between both compartments), were obtained by curve-fitting techniques (Hermens et al., to be published). However, an assumption has to be made regarding the release function \( f(t) \).

Two different hypotheses concerning \( f(t) \) were proposed as shown in Figure 2. In case A, we assume that necrosis is a multiplicative process; i.e., local degradation of cells has an amplifying effect on the necrosis of adjacent tissue, for instance, because of the release of cell contents, e.g., potassium. It can be shown
(Aitchison and Brown, 1963) that, under these circumstances, \( f(t) \) will be a log normal function given by

\[
f(t) = \frac{Q}{\sigma \sqrt{2\pi}} \exp \left( -0.5 \left( \frac{\ln t - \mu}{\sigma} \right)^2 \right)
\]

This is a three-parameter function in which \( Q \) is the total extra release of enzyme per liter vascular volume.

In case B, we assume that, after a period of ischemia, the majority of cells become permeable in a relatively short lapse of time (for instance, in a few minutes). This results in a sudden maximal release of diffusing enzymes with an exponential fall-off which is described by the following function:

\[
f(t) = Q_b \exp(-b(t-t_p)) \quad t \geq t_p
\]

which is again a three-parameter function with total release \( Q \).

RESULTS

As reported earlier (Hemker et al. 1972), the biphasic disappearance shown in Figure 1 is only observed for PHI, meaning that the plasma clearance curves for CPK, GOT, and LDH (\( \alpha \)-HBDH) are monoexponential. This phenomenon is caused by the fact that the enzyme release from the infarcted tissue continues for an appreciable period of time (about 34 hours for patients treated with urokinase and about 48 hours for untreated patients; see Figure 5). Owing to this tailing release, the fast phase of the clearance curve will not be observed in

\[\text{Figure 1. Two-compartment model.}\]
Figure 2. Two hypotheses regarding necrosis; A=multiplicative necrosis, B=sudden necrosis.

those cases where the exchange by diffusion ($P$) is fast compared to the clearance ($k$).

PHI is the only enzyme which is metabolized fast enough to show a biphasic disappearance of those patients with a relatively short period of enzyme release (mostly urokinase-treated patients).

The results of curve fitting for PHI showed that, in all cases, the assumption of multiplicative necrosis gave a better fit than the assumption of sudden necrosis; for more details, see the work of Hermens et al. (to be published). The best fit parameter values obtained for $P$ and $V_2/V_1$ are (for PHI):

$$P = 0.15 \pm 0.1 \text{ (liter/hour)}$$

$$V_2/V_1 = 0.30 \pm 0.12$$

For the molecular weights, the following values were found:

- LDH ($\alpha$-HBDH) $M = 145,000$
- PHI $M = 98,000$
- CPK $M = 82,000$
- GOT $M = 80,000$

All values are $\pm 5,000$.

As the diffusion constants of proteins are not very sensitive to molecular weight (Schultze and Heremans, 1966), it is improbable that the values for $P$ and $V_2/V_1$ will differ much from those found for PHI. Values (6) were therefore used in a routine computer program for all enzymes. In this program, the slow phase of the clearance curve is used to calculate $k$. Subsequently, the extravascular concentrations, the release function $f(t)$, and the total release are calculated from the plasma concentrations. The results are shown in Figure 3.
Figure 3. Patient 8. 1 = measured plasma concentrations. 2 = calculated extravascular concentrations. 3 = calculated enzyme release/hour. 4 = calculated total enzyme release.

Figure 4 shows the correlations between the calculated total release $Q$ for the different enzymes compared to LDH. As the clearance for LDH ($\alpha$-HBDH) is slow (cf. Table 3), this enzyme is the least sensitive to the irregularities in the release and was therefore chosen as reference. The systematic error in $Q_{\text{LDH}}$ corresponding to the uncertainty in $P$ and $V_2/V_1$ is estimated at 10–15%.

The correlation for CPK is not satisfactory, possibly attributable to the fact that this is the only enzyme that showed an unpredictable denaturation during in vitro studies (Witteveen, 1972). This phenomenon could invalidate our assumption of absence of extravascular elimination for this enzyme.

The results of four in vitro experiments of anoxic incubation of tissue are
shown in Table 1. As seen from Figure 4 and Table 1, the calculated total amounts of enzyme released from the infarcted area in patients exhibit approximately the same ratio as the amounts released in vitro. However, if we compare these in vitro values with the activities measured in fresh tissue (Table 2), we find that, for LDH (α-HBDH) and PHI, the original activities are recovered but, for GOT and CPK, roughly one-third of the activity has disappeared by a local process which apparently (also) proceeds in vitro.

Table 3 shows the calculated clearance constants $k$, total enzyme release $Q$, and equivalent amount of heart tissue $A$ in grams for all patients except patient 15; in this patient, the levels were too low to permit calculation of LDH, GOT, and PHI.
Table 1. In vitro enzyme release from human heart tissue incubated in plasma*

<table>
<thead>
<tr>
<th>Experiment</th>
<th>LDH</th>
<th>o-HBDH</th>
<th>GOT</th>
<th>CPK</th>
<th>PHI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td>A</td>
</tr>
<tr>
<td>1</td>
<td>122</td>
<td>21</td>
<td>99</td>
<td>19</td>
<td>43</td>
</tr>
<tr>
<td>2</td>
<td>136</td>
<td>23</td>
<td>87</td>
<td>16</td>
<td>23</td>
</tr>
<tr>
<td>3</td>
<td>127</td>
<td>33</td>
<td>87</td>
<td>21</td>
<td>35</td>
</tr>
<tr>
<td>4</td>
<td>89</td>
<td>20</td>
<td>64</td>
<td>15</td>
<td>32</td>
</tr>
<tr>
<td>Mean</td>
<td>118</td>
<td>24</td>
<td>84</td>
<td>18</td>
<td>34</td>
</tr>
</tbody>
</table>

* Activities expressed in I.U./g wet tissue. A, activity in plasma; B, residual tissue activity after 100 hours' incubation.

The amounts A were calculated for LDH by multiplying $Q_{LDH}$ by 1.20 to account for the residual tissue activity (see Table 1) and by the vascular volume, and dividing by 128 (see Table 2). For the other enzymes, the calculated $Q$ was first transformed into the corresponding $Q_{LDH}$ by means of the best fit equations given in Figure 4, followed by the same procedure. The effect of urokinase is shown in two ways. Table 4 gives the time of maximal plasma activity in hours after the onset of severe symptoms. As can be seen from this table, there is a considerable shortening for patients treated with urokinase. The same phenomenon is observed in Figure 5, where the calculated enzyme release $f(t)$ in I.U./liter/hours has been averaged for each group of patients.

DISCUSSION

The effect of urokinase in patients presenting electrocardiographic evidence of necrosis, such as elevation of the ST-segment, has been revealed in the multi-centered European Urokinase Trial in myocardial infarction. It could be demon-

Table 2. Human heart tissue enzyme activity*

<table>
<thead>
<tr>
<th></th>
<th>LDH</th>
<th>o-HBDH</th>
<th>GOT</th>
<th>CPK</th>
<th>PHI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>128</td>
<td>101</td>
<td>96</td>
<td>370</td>
<td>143</td>
</tr>
<tr>
<td>S.D.</td>
<td>15.4</td>
<td>11.1</td>
<td>18.2</td>
<td>37.0</td>
<td>14.3</td>
</tr>
</tbody>
</table>

*Activities expressed in I.U./g wet tissue (results of 15 determinations).
Table 3. Calculated parameters*

<table>
<thead>
<tr>
<th>Patient</th>
<th>LDH</th>
<th>α-HBDH</th>
<th>GOT</th>
<th>CPK</th>
<th>PHI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>k</td>
<td>Q</td>
<td>A</td>
<td>k</td>
<td>Q</td>
</tr>
<tr>
<td>1 φ</td>
<td>0.0126</td>
<td>2,113</td>
<td>58</td>
<td>0.0125</td>
<td>1,533</td>
</tr>
<tr>
<td>2 φ</td>
<td>0.0134</td>
<td>2,042</td>
<td>52</td>
<td>0.0113</td>
<td>1,483</td>
</tr>
<tr>
<td>3</td>
<td>0.0157</td>
<td>1,699</td>
<td>45</td>
<td>0.0164</td>
<td>1,240</td>
</tr>
<tr>
<td>4</td>
<td>0.0194</td>
<td>1,253</td>
<td>44</td>
<td>0.0202</td>
<td>957</td>
</tr>
<tr>
<td>5</td>
<td>0.0131</td>
<td>1,819</td>
<td>39</td>
<td>0.0133</td>
<td>1,423</td>
</tr>
<tr>
<td>6</td>
<td>0.0139</td>
<td>1,469</td>
<td>34</td>
<td>0.0167</td>
<td>1,145</td>
</tr>
<tr>
<td>7</td>
<td>0.0182</td>
<td>1,131</td>
<td>32</td>
<td>0.0181</td>
<td>917</td>
</tr>
<tr>
<td>8</td>
<td>0.0157</td>
<td>1,355</td>
<td>36</td>
<td>0.0189</td>
<td>1,038</td>
</tr>
<tr>
<td>9</td>
<td>0.0129</td>
<td>1,090</td>
<td>38</td>
<td>0.0134</td>
<td>906</td>
</tr>
<tr>
<td>10 φ</td>
<td>0.0102</td>
<td>969</td>
<td>27</td>
<td>0.0130</td>
<td>785</td>
</tr>
<tr>
<td>11 φ</td>
<td>0.0082</td>
<td>1,134</td>
<td>29</td>
<td>0.0086</td>
<td>855</td>
</tr>
<tr>
<td>12 φ</td>
<td>0.0135</td>
<td>928</td>
<td>22</td>
<td>0.0122</td>
<td>634</td>
</tr>
<tr>
<td>13</td>
<td>0.0274</td>
<td>664</td>
<td>17</td>
<td>0.0243</td>
<td>535</td>
</tr>
<tr>
<td>14</td>
<td>0.0124</td>
<td>639</td>
<td>17</td>
<td>0.0121</td>
<td>442</td>
</tr>
<tr>
<td>15</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*k, first order clearance constant (hours)^{-1}; Q, total enzyme release in I.U./liter vascular volume; A, equivalent amount of heart tissue (g) (see text); and φ, patients treated with urokinase.
Table 4. Time of maximal plasma enzyme activity*

<table>
<thead>
<tr>
<th></th>
<th>LDH</th>
<th>α-HBDH</th>
<th>GOT</th>
<th>CPK</th>
<th>PHI</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>37.7 (6.3)</td>
<td>39.1 (7.0)</td>
<td>27.6 (4.9)</td>
<td>22.9 (5.4)</td>
<td>22.2 (5.3)</td>
</tr>
<tr>
<td>B</td>
<td>25.7 (6.3)</td>
<td>25.7 (6.3)</td>
<td>19.6 (4.2)</td>
<td>17.3 (3.6)</td>
<td>16.8 (2.8)</td>
</tr>
</tbody>
</table>

*Values are expressed as means, with S.D. shown in parentheses. A, mean value for control patients ($N = 10$); B, mean value for patients treated with urokinase ($N = 5$). Difference between A and B is significant at a 0.02 level for LDH, α-HBDH, and GOT, and at a 0.05 level for CPK and PHI (Wilcoxon).

...strated that the electrocardiogram of patients treated with urokinase showed a more rapid normalization of the ST-segment as compared to the control group (Burkart et al., 1973).

As yet, no important therapeutic advantages of thrombolytic agents have been shown for AMI. Clinical trials on urokinase and another thrombolytic agent, streptokinase, revealed no appreciable effect on mortality in patients treated in coronary care units. In some earlier studies (Verstraete, 1973) in which patients were not treated in coronary care units, a favorable effect was found in trials with streptokinase. Whether this effect implies that there have been fewer fatal arrhythmias in the treated group, a finding which could be explained, for example, by a shorter period of tissue necrosis and, thus, a shorter period of electrical instability, remains to be demonstrated.

The two largest infarctions were found in urokinase-treated patients, with the result that this group showed a somewhat larger average enzyme release than did the control group. This effect is not significant in a rank test (see Table 4) and

Figure 5. Averaged release functions $f(t)$ for LDH.
might have been caused by the fact that the urokinase treatment was given to early recognized and hospitalized patients, the group that tends to present the larger infarctions. However, it remains to be answered whether urokinase, apart from accelerating the enzyme release, could also enhance it.

As regards the quantitation of the amount of necrotic tissue, it should be noted that, although we account for the amount of enzyme that is not released in vitro (20% for LDH) and although the release in vitro shows the same ratio for the amounts of different enzymes as the release in vivo, there might be an over-all underestimation due to local in vivo breakdown of tissue, e.g., by inflammatory processes.

Experiments in which CPK release was studied after experimental AMI in dogs showed that less than 30% of total tissue CPK appeared in the circulation (Shell, Kjekshus, and Sobel, 1971). However, the time course of plasma enzyme activity in dogs differs considerably from that in man; therefore, caution should be used before applying these data in studies of infarction in man.

REFERENCES


HERMENS, W. TH., S. A. G. J. WITTEVEEN, L. HOLLAAR, and H. C. HEMKER. Study of myocardial necrosis after acute myocardial infarction in man by means of plasma enzyme levels. (To be published).


Mailing address:
Dr. S. A. G. J. Witteveen,
Department of Cardiology, University Hospital,
Rijnsburgerweg 10, Leiden (The Netherlands).